In a landmark move, the U.S. Food and Drug Administration (FDA) has issued its first draft guidance concerning clinical trials with psychedelic drugs. This monumental step marks a new era in the exploration of the therapeutic potentials of these substances. The guidance is aimed at advising researchers on the design and conduct of clinical studies involving psychedelic drugs.
Religious Freedom Restoration Act of 1993 – Prohibits any agency, department, or official of the United States or any State (the government) from substantially burdening a person’s exercise of religion even if the burden results from a rule of general applicability, except that the government may burden a person’s exercise of religion only if it demonstrates that application of the burden to the person: (1) furthers a compelling governmental interest; and (2) is the least restrictive means of furthering that compelling governmental interest.
